US FDA Biologics Designation As Price Protection: Lilly Charts New Course With Retatrutide

An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.